SCHEMBL30358166

SCHEMBL30358166

Cn1c(=O)[nH]c2nc([S+](C)[O-])ncc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 11/20 0.43
▸ PDE3A Q14432 11/20 0.43
▸ PDE2A O00408 8/20 0.43
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ LMNA P02545 3/20 0.36
▸ ADORA2A P29274 3/20 0.36
▸ ADORA2B P29275 3/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ PMP22 Q01453 1/20 0.36
▸ APAF1 O14727 1/20 0.35
▸ CASP6 P55212 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ P2RY12 Q9H244 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349996 0.74 PDE3B (0.47) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL10006861 0.74 PDE3B (0.47) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL30358089 0.72 PDE3B (0.49) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL30358054 0.71 PDE3B (0.44) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL2734677 0.69 MAPK8 (0.38) PDE3BPDE3AALDH1A1KDM4EGLA
SCHEMBL3663241 0.67 APAF1 (0.44) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL29361697 0.67 APAF1 (0.44) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL29580870 0.67 XDH (0.35) —
SCHEMBL20157445 0.67 PDE3B (0.45) PDE3BPDE3APDE2AALDH1A1KDM4E
SCHEMBL31465468 0.66 XDH (0.41) PDE3BPDE3APDE2AHPGDADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 PDE3B 447/4885PDE3A 209/4885PDE2A 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback